NCT05696483View on ClinicalTrials.gov

Phase 1 Study of OLX-07010 in Healthy Adult and Elderly Participants

PHASE1Enrolling by invitationINTERVENTIONAL

Enrollment

88

Participants

Timeline

Start Date

January 20, 2023

Primary Completion Date

January 2, 2026

Study Completion Date

February 1, 2026

Conditions

Alzheimer Disease

Interventions

DRUG

OLX-07010 Active

25 and 75 mg capsules

DRUG

OLX-07010 Placebo

25 and 75 mg capsules

Trial Locations (1)

91206

California Clinical Trials Medical Group, Inc, Glendale

Sponsors

Lead Sponsor

Oligomerix, Inc

All Listed Sponsors

lead

Oligomerix, Inc

INDUSTRY

NCT05696483 - Phase 1 Study of OLX-07010 in Healthy Adult and Elderly Participants | Biotech Hunter | Biotech Hunter